Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

143.18
+2.471.76%
Post-market: 142.40-0.7800-0.54%19:30 EDT
Volume:1.65M
Turnover:235.71M
Market Cap:14.60B
PE:20.98
High:144.56
Open:141.41
Low:140.36
Close:140.71
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:1.03
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.95
PE(LYR):30.66

Loading ...

What Neurocrine Biosciences (NBIX)'s New CRENESSITY CAH Data Means For Shareholders

Simply Wall St.
·
Jun 22

Deutsche Bank Raises Neurocrine Biosciences Price Target to $170 From $155, Maintains Hold Rating

MT Newswires Live
·
Jun 22

Neurocrine Biosciences, Inc. : Deutsche Bank Raises Target Price to $170 From $155

THOMSON REUTERS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

Neurocrine’s Valbenazine Huntington Study Completion Signals Next Phase for NBIX Investors

TIPRANKS
·
Jun 18

Neurocrine presents first retrospective case series of Crenessity

TIPRANKS
·
Jun 16

Neurocrine presents two-year Crenessity data

TIPRANKS
·
Jun 15

Neurocrine reports 2-year Phase 3 CAHtalyst Adult data showing cardiometabolic gains with CRENESSITY in classic CAH

Reuters
·
Jun 15

Vir Biotechnology names Timothy Coughlin to board, taps him as audit committee chair

Reuters
·
Jun 11

Neurocrine Biosciences director Stephen A. Sherwin disposes of USD 4.12 million in common shares

Reuters
·
Jun 10

Neurocrine director Leslie V Norwalk disposes of USD 210,071.63 in common shares

Reuters
·
Jun 09

Neurocrine Biosciences Late-Stage Study Shows Promising Results for Tardive Dyskinesia Drug

MT Newswires Live
·
Jun 09

Neurocrine reports new post-hoc data from KINECT 4 trial

TIPRANKS
·
Jun 09

Neurocrine says post-hoc KINECT 4 data show 94% response or remission with Ingrezza in tardive dyskinesia

Reuters
·
Jun 09

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of Ingrezza® (Valbenazine) Capsules Across a Broad Range of Patients

THOMSON REUTERS
·
Jun 09

Neurocrine presents new data showing Improvements with INGREZZA

TIPRANKS
·
Jun 08

Neurocrine says clinician-reported analysis shows rapid TD improvement with Ingrezza in patients with developmental disabilities

Reuters
·
Jun 08

Neurocrine Biosciences CHRO Julie Cooke disposes of common shares worth $5.78 million

Reuters
·
Jun 05

Movement Alert|Neurocrine Biosciences Rises 5.85% in Regular Trading, RBC Raises Target Price on Crenessity Commercial Outlook

Market Focus
·
Jun 04

Neurocrine Biosciences CSO Jude Onyia disposes of common shares worth $1.76 million

Reuters
·
Jun 03